EMA Withdrawn: Aerivio Spiromax (salmeterol xinafoate;fluticasone propionate) — Teva B.V.

View source ↗

Summary

EMA withdrew Aerivio Spiromax (salmeterol xinafoate; fluticasone propionate) from Teva B.V., a pulmonary disease and asthma medication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Aerivio Spiromax (salmeterol xinafoate; fluticasone propionate)

Snippet

Status: Withdrawn. Therapeutic area: Pulmonary Disease, Chronic Obstructive;Asthma. MAH: Teva B.V.. Decision date: 04/10/2019